Rössner S, Weiner L
Eur J Clin Pharmacol. 1983;24(5):573-7. doi: 10.1007/BF00542203.
Several beta-blockers increase VLDL-TG and decrease HDL-cholesterol concentrations. The underlying mechanism is not yet clear. Some studies have suggested that the effect is less pronounced during treatment with selective beta-blockers. The effects of 2 such drugs, metoprolol 200 mg/day and atenolol 50 mg/day, have been compared in 50 hypertensive patients (WHO Stage I-II), mean age 47 years. Serum lipoproteins were determined in 20 patients before treatment and after treatment with either drug for 3 months. Both drugs were equally effective in reducing blood pressure. After atenolol the initial VLDL-cholesterol concentration of 1.04 mmol/l had not changed, but it rose to 1.29 mmol/l after metoprolol (p less than 0.05). The HDL-cholesterol concentration 1.42 mmol/l did not fall during atenolol treatment, but during metoprolol there was a small reduction to 1.31 mmol/l (p less than 0.05). Hyperlipoproteinaemia is common in hypertensive patients, 40% of the present group had hypertriglyceridaemia and 25% had hypercholesterolaemia. Thus, atenolol 50 mg was found not to affect lipoproteins, whereas metoprolol 200 mg increased the VLDL concentration in 75% of the patients.
几种β受体阻滞剂会升高极低密度脂蛋白甘油三酯(VLDL-TG)并降低高密度脂蛋白胆固醇(HDL-胆固醇)浓度。其潜在机制尚不清楚。一些研究表明,在使用选择性β受体阻滞剂治疗期间,这种影响不太明显。已在50名高血压患者(世界卫生组织I-II期)中比较了两种此类药物(美托洛尔200毫克/天和阿替洛尔50毫克/天)的效果,这些患者平均年龄为47岁。在20名患者治疗前以及用任一药物治疗3个月后测定血清脂蛋白。两种药物在降低血压方面同样有效。服用阿替洛尔后,初始极低密度脂蛋白胆固醇浓度1.04毫摩尔/升未发生变化,但服用美托洛尔后升至1.29毫摩尔/升(p<0.05)。高密度脂蛋白胆固醇浓度1.42毫摩尔/升在阿替洛尔治疗期间未下降,但在美托洛尔治疗期间略有下降至1.31毫摩尔/升(p<0.05)。高脂蛋白血症在高血压患者中很常见,本研究组中40%的患者有高甘油三酯血症,25%的患者有高胆固醇血症。因此,发现50毫克阿替洛尔不影响脂蛋白,而200毫克美托洛尔使75%的患者极低密度脂蛋白浓度升高。